DK3006443T3 - benzothiophene - Google Patents

benzothiophene Download PDF

Info

Publication number
DK3006443T3
DK3006443T3 DK14807340.6T DK14807340T DK3006443T3 DK 3006443 T3 DK3006443 T3 DK 3006443T3 DK 14807340 T DK14807340 T DK 14807340T DK 3006443 T3 DK3006443 T3 DK 3006443T3
Authority
DK
Denmark
Prior art keywords
compound
methyl
salt
pain
chloro
Prior art date
Application number
DK14807340.6T
Other languages
Danish (da)
English (en)
Inventor
Tsukasa Ishihara
Kazuhiro Ikegai
Ikumi Kuriwaki
Hiroyuki Hisamichi
Nobuaki Takeshita
Ryuichi Takezawa
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Application granted granted Critical
Publication of DK3006443T3 publication Critical patent/DK3006443T3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK14807340.6T 2013-06-06 2014-06-06 benzothiophene DK3006443T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013119416 2013-06-06
PCT/JP2014/065141 WO2014196644A1 (ja) 2013-06-06 2014-06-06 ベンゾチオフェン化合物

Publications (1)

Publication Number Publication Date
DK3006443T3 true DK3006443T3 (en) 2018-06-25

Family

ID=52005968

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14807340.6T DK3006443T3 (en) 2013-06-06 2014-06-06 benzothiophene

Country Status (32)

Country Link
US (2) US8981119B2 (enExample)
EP (1) EP3006443B1 (enExample)
JP (1) JP6314978B2 (enExample)
KR (1) KR102253721B1 (enExample)
CN (1) CN105263926B (enExample)
AR (1) AR096544A1 (enExample)
AU (1) AU2014275768B2 (enExample)
BR (1) BR112015030533B1 (enExample)
CA (1) CA2914606C (enExample)
CY (1) CY1120341T1 (enExample)
DK (1) DK3006443T3 (enExample)
ES (1) ES2671818T3 (enExample)
HR (1) HRP20180722T1 (enExample)
HU (1) HUE038920T2 (enExample)
IL (1) IL242800B (enExample)
LT (1) LT3006443T (enExample)
MX (1) MX2015016743A (enExample)
MY (1) MY199155A (enExample)
NO (1) NO3006443T3 (enExample)
PH (1) PH12015502637B1 (enExample)
PL (1) PL3006443T3 (enExample)
PT (1) PT3006443T (enExample)
RS (1) RS57250B1 (enExample)
RU (1) RU2667507C2 (enExample)
SG (1) SG11201509989VA (enExample)
SI (1) SI3006443T1 (enExample)
SM (1) SMT201800306T1 (enExample)
TR (1) TR201808724T4 (enExample)
TW (1) TWI624466B (enExample)
UA (1) UA117484C2 (enExample)
WO (1) WO2014196644A1 (enExample)
ZA (1) ZA201508866B (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022541634A (ja) * 2019-07-23 2022-09-26 アステラス ファーマ グローバル ディベロップメント,インコーポレーテッド. 疼痛に関連する睡眠障害を治療する方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614639A (en) * 1995-03-31 1997-03-25 Eli Lilly And Company Process for preparing 2-substituted benzo[b]thiophene compounds and intermediates thereof
US20040116405A1 (en) 2001-02-06 2004-06-17 Brian Cox Use of bicyclic esters or amides for the treatment of diseases responsive to enhanced potassium channel activity
WO2003005025A1 (en) * 2001-07-03 2003-01-16 Biovitrum Ab Methods for identifying compounds modulating the activity of ppar-gamma
US7589116B2 (en) 2003-04-03 2009-09-15 Merck & Co. Inc. Biaryl substituted pyrazoles as sodium channel blockers
CN1852906A (zh) 2003-07-15 2006-10-25 史密丝克莱恩比彻姆公司 新化合物
WO2008054435A2 (en) * 2006-01-09 2008-05-08 The Regents Of The University Of California Use of sk channel activators to prevent relapse/reinstatement of drugs of abuse
WO2009035671A1 (en) * 2007-09-12 2009-03-19 Janssen Pharmaceutica N.V. Substituted nitrogen-containing heteroaryl derivatives useful as modulators of the histamine h4 receptor
KR20110096541A (ko) 2008-11-10 2011-08-30 베링거 인겔하임 인터내셔날 게엠베하 중간-전도성 칼슘-활성화된 칼륨 채널을 통해 세포-세포 융합을 조절하기 위한 조성물 및 방법
AR090037A1 (es) 2011-11-15 2014-10-15 Xention Ltd Derivados de tieno y/o furo-pirimidinas y piridinas inhibidores de los canales de potasio

Also Published As

Publication number Publication date
PH12015502637B1 (en) 2019-02-08
US9399038B2 (en) 2016-07-26
EP3006443B1 (en) 2018-04-25
BR112015030533B1 (pt) 2023-02-28
AU2014275768A1 (en) 2015-12-17
CN105263926A (zh) 2016-01-20
BR112015030533A2 (pt) 2020-10-20
JPWO2014196644A1 (ja) 2017-02-23
IL242800A0 (en) 2016-02-01
EP3006443A4 (en) 2016-12-21
US20150133433A1 (en) 2015-05-14
TR201808724T4 (tr) 2018-07-23
CN105263926B (zh) 2018-05-11
CA2914606A1 (en) 2014-12-11
AR096544A1 (es) 2016-01-13
HUE038920T2 (hu) 2018-12-28
RS57250B1 (sr) 2018-07-31
CY1120341T1 (el) 2019-07-10
CA2914606C (en) 2021-03-23
AU2014275768B2 (en) 2017-12-14
TW201536775A (zh) 2015-10-01
NO3006443T3 (enExample) 2018-09-22
WO2014196644A1 (ja) 2014-12-11
PL3006443T3 (pl) 2018-09-28
IL242800B (en) 2019-06-30
MY199155A (en) 2023-10-18
KR102253721B1 (ko) 2021-05-18
PH12015502637A1 (en) 2016-03-07
US8981119B2 (en) 2015-03-17
HRP20180722T1 (hr) 2018-06-15
SI3006443T1 (en) 2018-08-31
SMT201800306T1 (it) 2018-07-17
PT3006443T (pt) 2018-06-07
UA117484C2 (uk) 2018-08-10
SG11201509989VA (en) 2016-01-28
KR20160015281A (ko) 2016-02-12
RU2015152150A (ru) 2017-07-13
ZA201508866B (en) 2017-11-29
EP3006443A1 (en) 2016-04-13
JP6314978B2 (ja) 2018-04-25
RU2667507C2 (ru) 2018-09-21
ES2671818T3 (es) 2018-06-08
TWI624466B (zh) 2018-05-21
US20140364421A1 (en) 2014-12-11
LT3006443T (lt) 2018-07-10
HK1215570A1 (zh) 2016-09-02
MX2015016743A (es) 2016-03-21

Similar Documents

Publication Publication Date Title
CA2671080A1 (en) Carboxylic acid derivatives
CA2650124A1 (en) Oxadiazolidinedione compound
KR20150132556A (ko) 과다증식성 장애의 치료를 위한 3-아세틸아미노-1-(페닐-헤테로아릴-아미노카르보닐 또는 페닐-헤테로아릴-카르보닐아미노)벤젠 유도체
AU2012337781A1 (en) Dihydroxy aromatic heterocyclic compound
AU2007282465B2 (en) Sulfonamide compound or salt thereof
CA2793856A1 (en) Tetrahydrobenzothiophene compound
KR20090114439A (ko) 아실구아니딘 유도체
AU2006319916A1 (en) 2-aminobenzamide derivative
WO2011034078A1 (ja) グリシン化合物
DK2987793T3 (en) Heterocyclic Acetic Acid Amide Compound
DK3006443T3 (en) benzothiophene
RU2526253C9 (ru) Диаминогетероциклическое карбоксамидное соединение
CN106573928A (zh) 2‑氨基噻唑衍生物或其盐
HK1215570B (en) Bensothiophene compound